Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Meta Expands AI Training With Employee Activity Tracking Tools 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
VANCOUVER, B.C. and DOYLESTOWN, Pa., March 23, 2017 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company has appointed Daniel Burgess to the Board of Directors and Audit Committee effective immediately.
Mr. Burgess has more than 25 years of executive level operating experience in biotech companies, including substantial experience in the anti-infective field. He is currently a Venture Partner at SV Life Sciences, is Chairman of the Board of Nabriva Therapeutics (NASDAQ:NBRV) and is on the board of Cidara Therapeutics (NASDAQ:CDTX) as well as several private biotechnology companies. In addition, he is Chairman of Biocom, the life science industry organization of California that represents more than 800 member companies. Prior to his current roles, Mr. Burgess was President of Rempex Pharmaceuticals, a company he co-founded in 2011 and subsequently sold to The Medicines Company in December 2013. Prior to Rempex, Mr. Burgess was President and Chief Executive Officer of Mpex Pharmaceuticals, Inc., which was acquired by Aptalis Pharma Inc. (now Allergan) in 2011. Previously, Mr. Burgess was Chief Operating Officer and Chief Financial Officer of Harbor BioSciences, Inc., formerly Hollis-Eden Pharmaceuticals, Inc. Prior to Hollis-Eden, Mr. Burgess spent ten years with Gensia Sicor, Inc. (acquired by Teva Pharmaceutical Industries Limited) where he held a variety of executive level positions with responsibility for overall finance for the company as well as a number of different operating units. Mr. Burgess holds a B.A. in economics from Stanford University and an M.B.A. from Harvard Business School.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Doylestown, PA. For more information, visit www.arbutusbio.com.
Contact Information Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604-419-3200 Email: [email protected] Media David Schull Russo Partners Phone: 858.717.2310 Email: [email protected]
